CJC-1295 + Ipamorelin

Published CJC-1295 clinical research has studied dose-dependent growth hormone and IGF-1 responses using microgram-per-kilogram dosing models, including ranges around 30 to 60 mcg/kg in tolerability-focused contexts and higher investigational ranges in early trials. Ipamorelin research is more limited and is largely experimental or preclinical, with its main value coming from its selective growth hormone secretagogue profile.

Researcher-reported exploratory blend ranges often discuss approximately 100 mcg of CJC-1295 paired with 100-300 mcg of Ipamorelin per administration, commonly studied once daily or around evening/fasted research windows. Other research discussions use several-times-weekly or 5-days-on/2-days-off schedules, and cycle lengths are often described in the 8-12 week range depending on the model and endpoint. These ranges should not be presented as recommendations. Protocol design depends on whether the study material uses CJC-1295 with DAC or without DAC, the ratio of the blend, the study model, concentration, frequency, endocrine markers being monitored, and the intended research outcome.

A lyophilized CJC-1295 + Ipamorelin vial can produce different concentrations depending on the total peptide content and the volume of diluent used. The final concentration depends on the blend ratio, total milligrams in the vial, and the selected reconstitution volume. Store unopened lyophilized vials refrigerated when possible and protected from direct light, heat, and repeated temperature changes. Once reconstituted, keep refrigerated and avoid unnecessary warming, freezing, or agitation. If mixing is needed after adding diluent, gently swirl the vial rather than shaking it.